[Medication Therapy for Soft Tissue Sarcoma (Current Status and Future Perspective)].
Doxorubicin and ifosfamide have played a major role in the medical therapy for soft tissue sarcoma (STS). In the last few years, new cytotoxic drugs (eribulin, trabectedin, etc.) and molecular targeting drugs(pazopanib, which is a tyrosine kinase inhibitor of VEGFR1-3, and PDGFR) have been introduced in clinical practice for the treatment of STS. These new drugs are expected to improve the outcome of medical therapy for STS in the future.